Regulation of G protein-coupled receptor signaling and trafficking
G 蛋白偶联受体信号传导和运输的调节
基本信息
- 批准号:9978885
- 负责人:
- 金额:$ 50.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistArrestinsBindingBiochemicalCellsComplexDevelopmentDiseaseEndocytosisEnvironmentG Protein-Coupled Receptor SignalingG protein coupled receptor kinaseG-Protein-Coupled ReceptorsGRK5 geneGTP-Binding Protein alpha Subunits, GsGTP-Binding ProteinsHeterotrimeric GTP-Binding ProteinsHot SpotLaboratoriesLigandsMediatingMolecular ConformationMolecular StructureMolecular and Cellular BiologyPharmaceutical PreparationsPhosphotransferasesPlayProcessRegulationResearchRoleSignal TransductionStructureTherapeuticTimeX-Ray Crystallographybeta-2 Adrenergic Receptorsbeta-arrestinbiophysical analysisdesensitizationinsightreceptorreceptor functionresidencetrafficking
项目摘要
G protein-coupled receptors (GPCRs) play an essential role in coordinating the ability of cells to rapidly
respond to their environment. Agonist binding to a GPCR promotes initial activation of heterotrimeric G
proteins, which mediates downstream signaling. Agonist-occupied GPCRs then interact with GPCR kinases
(GRKs), which specifically phosphorylate the receptor, and arrestins, which bind to GRK-phosphorylated
receptors and function in GPCR desensitization, endocytosis, and signaling. A central question that drives
current GPCR research involves understanding the dynamics and structures of GPCR interactions with G
proteins, GRKs and arrestins. My laboratory is currently using a variety of strategies including X-ray
crystallography, biochemical and biophysical analysis, and molecular and cellular biology to better understand
the dynamics of GPCR regulation by GRKs and arrestins and the potential role of these processes in disease.
In this application, we propose to address four questions that are central to understanding the mechanisms
involved in GRK and arrestin regulation of GPCR signaling and trafficking. Can we obtain structural and
dynamic insight on a GPCR/GRK complex? While we currently know little about the critical regions that
mediate GRK interaction with GPCRs or how this interaction ultimately regulates GRK activation, our
preliminary studies reveal three binding “hot spots” between the β2-adrenergic receptor (β2AR) and GRK5 and
suggest large conformational changes in GRK5 upon binding to the receptor. How does β-arrestin interact with
the β2-adrenergic receptor and β2-adaptin? β-arrestins play a central role in regulating GPCR signaling and
trafficking so further understanding these interactions has important implications. Moreover, structural
differences in the receptor when bound to its major downstream targets should provide insight on candidate
regions to target in order to selectively enhance or disrupt specific interactions. Do α-arrestins play a broad
role in regulating GPCR trafficking and signaling? We have found that the α-arrestin ARRDC3 functions as a
switch to modulate the endosomal residence time and subsequent intracellular signaling of the β2AR. We will
perform structure/function analysis of ARRDC3 interaction with the β2AR and assess whether ARRDCs have a
broad role in regulating GPCR function. What is the molecular and structural basis of biased agonism? While it
is evident that biased signaling through a number of GPCRs may ultimately prove to be of significant
therapeutic value, literally nothing is known about the structural and mechanistic basis by which ligands can
bias GPCR signaling. Overall, a more detailed understanding into these questions has tremendous
implications for the development of more effective drugs to treat a wide variety of diseases.
G蛋白偶联受体(GPCRs)在协调细胞快速凋亡的能力中起重要作用。
回应他们的环境。激动剂与GPCR的结合促进异源三聚体G
蛋白质,介导下游信号传导。激动剂占据的GPCR然后与GPCR激酶相互作用
(GRK),其特异性磷酸化受体,和抑制蛋白,其结合GRK-磷酸化受体。
受体和功能的GPCR脱敏,内吞作用和信号。一个核心问题,
目前的GPCR研究涉及了解GPCR与G
蛋白质GRKs和抑制蛋白我的实验室目前正在使用各种策略,包括X射线
晶体学、生物化学和生物物理分析以及分子和细胞生物学,以更好地了解
GRKs和抑制蛋白调控GPCR的动力学以及这些过程在疾病中的潜在作用。
在这个应用程序中,我们提出了四个问题,这是理解机制的核心
参与GRK和GPCR信号传导和运输的抑制蛋白调节。我们能否获得结构和
GPCR/GRK复合体的动态洞察力虽然我们目前对关键区域知之甚少,
介导GRK与GPCR的相互作用,或者这种相互作用最终如何调节GRK激活,我们的研究
初步研究揭示了β2-肾上腺素能受体(β2AR)和GRK 5之间的三个结合“热点”,
表明GRK 5在与受体结合后发生了大的构象变化。β-抑制蛋白如何与
β2-肾上腺素能受体和β2-适应素?β-抑制蛋白在调节GPCR信号传导中起核心作用,
因此,进一步了解这些相互作用具有重要意义。此外,结构
受体与其主要下游靶点结合时的差异应提供对候选者的了解。
靶向区域,以选择性地增强或破坏特定的相互作用。α-抑制蛋白是否发挥广泛的
在调控GPCR运输和信号传递中的作用?我们已经发现α-arrestin ARRDC 3作为一种
开关以调节β2AR的内体停留时间和随后的细胞内信号传导。我们将
进行ARRDC 3与β2AR相互作用的结构/功能分析,并评估ARRDC 3是否具有与β 2AR相互作用的功能。
在调节GPCR功能中的广泛作用。偏性激动作用的分子和结构基础是什么?虽然
很明显,通过许多GPCR的偏置信号可能最终被证明是重要的
尽管配体具有治疗价值,但从字面上讲,对配体可以
偏置GPCR信号传导。总的来说,对这些问题的更详细的理解具有巨大的意义。
这对开发更有效的药物来治疗各种疾病具有重要意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey L Benovic其他文献
Jeffrey L Benovic的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey L Benovic', 18)}}的其他基金
Training Grant in Cellular, Biochemical and Molecular Sciences
细胞、生化和分子科学培训补助金
- 批准号:
10655637 - 财政年份:2022
- 资助金额:
$ 50.7万 - 项目类别:
Structural and dynamic analysis of GRK interaction with G protein-coupled receptors
GRK 与 G 蛋白偶联受体相互作用的结构和动态分析
- 批准号:
9913308 - 财政年份:2018
- 资助金额:
$ 50.7万 - 项目类别:
Regulation of G protein-coupled receptor signaling and trafficking
G 蛋白偶联受体信号传导和运输的调节
- 批准号:
10214632 - 财政年份:2017
- 资助金额:
$ 50.7万 - 项目类别:
Project 3 - Biased Targeting of beta 2AR Signaling in Airway Disease
项目 3 - 气道疾病中 β2AR 信号传导的偏向靶向
- 批准号:
10465062 - 财政年份:2013
- 资助金额:
$ 50.7万 - 项目类别:
Project 3 - Biased Targeting of beta 2AR Signaling in Airway Disease
项目 3 - 气道疾病中 β2AR 信号传导的偏向靶向
- 批准号:
10683130 - 财政年份:2013
- 资助金额:
$ 50.7万 - 项目类别:
Project 3 - Biased Targeting of beta 2AR Signaling in Airway Disease
项目 3 - 气道疾病中 β2AR 信号传导的偏向靶向
- 批准号:
10238023 - 财政年份:2013
- 资助金额:
$ 50.7万 - 项目类别:
Training Program in Cellular, Biochemical, and Molecular Sciences
细胞、生化和分子科学培训项目
- 批准号:
8688268 - 财政年份:2012
- 资助金额:
$ 50.7万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 50.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 50.7万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 50.7万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 50.7万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 50.7万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 50.7万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 50.7万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 50.7万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 50.7万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 50.7万 - 项目类别:
Grant-in-Aid for Scientific Research (C)